<DOC>
	<DOC>NCT01600755</DOC>
	<brief_summary>The aim of this clinical study is to investigate the safety and feasibility of Autologous Muscle Derived Cells (AMDC; a preparation of a patient's own cells) injection into the anal sphincter for treatment of patients with fecal incontinence.</brief_summary>
	<brief_title>Autologous Cell Therapy for Treatment of Fecal Incontinence</brief_title>
	<detailed_description />
	<mesh_term>Fecal Incontinence</mesh_term>
	<criteria>Primary symptoms of fecal incontinence, as confirmed by patient medical history and physical examination Wexner score â‰¥ 9 Failed conservative treatment Gracilis sling repair or insertion of an artificial sphincter Inflammatory Bowel Disease Significant rectocele or rectal prolapse History of radiation treatment to the anal sphincter or adjacent structures Less than 18 years of age Pregnant, breastfeeding, or plans to become pregnant during the course of the study Neuromuscular disorder History of neoplasia within 5 years prior to enrollment, except for basal cell carcinoma, or is receiving or planning to receive anticancer medications Known bleeding diathesis or uncorrected coagulopathy Medical condition that would preclude treatment due to contraindications and/or warnings of concomitant medications or listed in the experimental product labeling Participating in another investigational drug or device study Unable or unwilling to provide informed consent Unable or unwilling to commit to the followup procedures</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Cell Therapy</keyword>
	<keyword>Autologous Cell Transplantation</keyword>
	<keyword>Muscle-derived Cell</keyword>
	<keyword>Anal Incontinence</keyword>
	<keyword>Rectal Diseases</keyword>
	<keyword>Intestinal Diseases</keyword>
	<keyword>Gastrointestinal Diseases</keyword>
	<keyword>Urinary Incontinence</keyword>
</DOC>